Inhibikase Therapeutics (IKT) Misses Q1 EPS by 10c
Tweet
Share
E-mailGet Alerts IKT Hot Sheet
Join SI Premium – FREE
Inhibikase Therapeutics (NASDAQ: IKT) reported Q1 EPS of ($0.10).
For earnings history and earnings-related data on Inhibikase Therapeutics (IKT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
- NANO Nuclear Announces Participation in Several Investor Conferences
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
